Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) has introduced Tanzeum (albiglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist, in pharmacies throughout the US, as a prescription injectable treatment for type 2 diabetes in adults.
Subscribe to our email newsletter
Tanzeum is a once weekly option for patients, in combination with some other glucose-lowering medicines.
In April 2014, the drug was approved by the US Food and Drug Administration as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
According to the company, the drug is not recommended as first-line therapy for patients inadequately controlled on diet and exercise.
GSK General Medicine business vice-president Cheryl MacDiarmid said: "With approximately 21 million adults diagnosed with diabetes in the US1, and up to 95% of those patients living with type 2 diabetes, we’re excited that for the appropriate patients Tanzeum is now available as a treatment option for healthcare professionals."
The company said that Tanzeum has not been studied in patients with a history of pancreatitis and other antidiabetic therapies should be considered in patients with a history of pancreatitis.
The medicine is also not indicated in the treatment of patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis.